Latest News & Updates

Breaking News

  • 30 minutes ago

  • Pharma Now Editorial Team

Regeneron Signs $2.32 Billion Deal with Parabilis for Helicon Peptide-Antibody Conjugates
Breaking News
Apothecon Pharma Appoints Shyamakant Giri as Group CEO to Lead India-US Operations

Pharma Now Editorial Team

Other trending news you may like to read

Regeneron Signs $2.32 Billion Deal with Parabilis for Helicon Peptide-Antibody Conjugates

Regeneron's $2.32B Parabilis deal brings Helicon peptide-antibody conjugates into GMP scope, raising new CMC and manufacturing challenges for the conjugate space.

Pharma Now Editorial Team

Pharma Now

Apothecon Pharma Appoints Shyamakant Giri as Group CEO to Lead India-US Operations

Apothecon Pharma names Shyamakant Giri Group CEO to unify strategy across its India and US operations, including Navinta LLC.

Pharma Now Editorial Team

Pharma Now

Monopar Publishes Phase 2 Data Showing ALXN1840 Improves Copper Balance in Wilson Disease Patients

Monopar's Phase 2 data in Hepatology Communications show ALXN1840 significantly improves copper balance in Wilson disease, reinforcing Phase 3 findings.

Pharma Now Editorial Team

Pharma Now

Eton Pharmaceuticals Secures U.S. Commercialization Rights to IMPAVIDO from Knight Therapeutics

Eton Pharmaceuticals takes U.S. commercialization of IMPAVIDO® (miltefosine) from Knight Therapeutics, effective September 26, 2026.

Pharma Now Editorial Team

Pharma Now